Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”).

Poseida Therapeutics Inc. and iTeos Therapeutics S.A., are revisiting their IPO plans after snagging mezzanine rounds. Another pair -- Akouos Inc. and Fusion Pharmaceuticals Inc. -- upped their

Read the full 625 word article

How to gain access

Continue reading with a
two-week free trial.